Introduction {#S1}
============

Systemic lupus erythematosus (SLE, lupus) is a multiorgan autoimmune disease, initially described on the basis of its cutaneous manifestations ([@B1]). During the nineteenth century, the true multisystem nature of the disease was recognized with the initial descriptions of severe brain involvement ([@B2], [@B3]). The first dedicated clinical studies of neurological dysfunction in lupus were reported in 1945 by David Daly ([@B4]). His observations were astute, noting a high degree of heterogeneity in the neurological manifestations, and a prominent contribution of neurovascular disease. Over the following decades, the effects of lupus on all levels of the nervous system have been recognized.

The diversity of neurological disease in lupus stimulated calls for a classification system to facilitate its clinical and scientific study ([@B5]). In 1999, the American College of Rheumatology (ACR) developed criteria for case definitions for neurolupus ([@B6]). These broadly distinguish between complications which affect the central nervous system and peripheral nervous system (Table [1](#T1){ref-type="table"} and Figure [1](#F1){ref-type="fig"}). While minor modifications have been proposed to these criteria, they have remained largely unchanged for almost two decades ([@B7], [@B8]). Neurological events have also been incorporated into diagnostic criteria for lupus, as well as outcome metrics such as the SLICC/ACR Damage index ([@B9], [@B10]).

###### 

Clinical syndromes seen in people with systemic lupus erythematosus.

                           Syndrome                                                                                                          Implicated mechanisms and potential therapeutic targets
  ------------------------ ----------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------
  CNS                      Large and small vessel disease                                                                                    Large vessel atheromatous disease ([@B57])Accelerated cerebral small vessel disease ([@B18])Antiphospholipid antibodies ([@B49])
  Seizures                 Unknown ([@B69])                                                                                                  
  Myelopathy               Antibody-mediated \[aquaporin-4, myelin oligodendrocyte glycoprotein (MOG)\] ([@B21], [@B147], [@B148])Vascular   
  Meningitis               Unknown ([@B78])                                                                                                  
  Movement disorder        Unknown ([@B84])                                                                                                  
  Demyelinating syndrome   Not clearly associated with SLE ([@B89])                                                                          
  Headache                 Not clearly associated with SLE ([@B90])                                                                          
  Psychiatric disease      Cytokine dysregulation ([@B107])Antibody-mediated (NMDA-R, Ribosomal-P) ([@B97])                                  
  Cognitive dysfunction    Cytokine dysregulation ([@B38])Small vessel disease ([@B18], [@B61])                                              
  PNS                      Peripheral neuropathy                                                                                             Vasculitis ([@B124])Antibody-mediated (ganglioside) ([@B149])
  Cranial neuropathy       VasculitisAntibody-mediated (aquaporin-4/MOG) ([@B132], [@B150])                                                  
  Myasthenia Gravis        Antibody-mediated (anti-AChR) ([@B151])                                                                           

![The spectrum of neurological disease in lupus. Lupus can affect all levels of the nervous system, including the brain and spinal cord, as well as the peripheral nervous system. See text for detailed descriptions of individual syndromes.](fimmu-09-01146-g001){#F1}

The development of the ACR neurolupus definitions helped stimulate the epidemiological study of neurological disease in lupus, and has demonstrated that nervous system involvement is a major negative determinant of quality of life ([@B11]--[@B13]). However, such studies have highlighted one of the major problems in the field---the issue of establishing a causal association between a neurological syndrome and lupus ([@B14]). For example, the ACR criteria include terms such as *headache* and *mood disorder* which are highly prevalent in the general population and observed at similar frequency in healthy, matched controls, as well as patients with other chronic inflammatory diseases ([@B15]). As such they are less likely to be caused directly by lupus. When "minor events" such as headache and anxiety disorders are included in population studies, then 40% of patients had at least one neuropsychiatric event ([@B12]). Exclusion of minor symptomatology leads to much improved specificity of the criteria ([@B15]). Neurological manifestations can occur at any stage of disease. Longitudinal studies of newly diagnosed patients show that neurological events attributable to lupus can occur around the time of diagnosis in approximately 5--10% of cases ([@B16]). Prospective studies show that major neurological events develop in about 5% of patients with SLE, followed over 3 years ([@B17]). Magnetic resonance imaging evidence (MRI) of brain changes indicating microvascular disease can develop early in disease course and in young patients ([@B18], [@B19]).

Much of the difficulty in classification stems from a comparative lack of understanding as to how neurological disease develops in people with lupus. It is notable that the ACR definitions focus largely on neurological syndromes, rather than pathophysiological mechanisms. This is in major contrast to renal lupus, where pathophysiological classification influences treatment and prognosis (Figure [2](#F2){ref-type="fig"}) ([@B20]). With the development of increasingly targeted treatments, an understanding of the molecular pathogenesis of brain disease is ever more important if it is to inform clinical trial design and, ultimately an individualized therapeutic approach.

![Classifying neurological disease in lupus. Both the brain and kidney can be severely affected in up to 10% of patients with lupus. **(A)** While lupus nephritis can present with different clinical syndromes, it is largely defined by a pathological classification of the renal biopsy. Image created with Biorender. **(B)** In contrast, neurological forms of lupus are usually classified according to neurological syndrome, and pathological material is rarely obtained. **(C)** We have an increasingly precise understanding of the syndrome previously described as "lupus myelopathy," T2-weighted magnetic resonance imaging of long inflammatory lesion in person with lupus shown, with high signal from within the thoracic spinal cord. A proportion of such spinal cord presentations are driven by antibodies directed against aquaporin-4, a glial water channel ([@B21]). Other cases are caused by spinal cord inflammation without these antibodies, while some cases are associated with spinal cord ischemia ([@B22], [@B23]). Each of these causes may require consideration of differing therapeutic approaches. As such, what was previously considered a single disease entity can be caused by differing pathogenic mechanisms, with implications for treatment and clinical trial design.](fimmu-09-01146-g002){#F2}

Pathophysiology of Neurological Disease in Lupus {#S2}
================================================

Genetics {#S2-1}
--------

Genome-wide association studies of large cohorts of lupus patients have identified an increasing number of associations with pathways involved in both the innate and adaptive immune systems ([@B24]). However, to date there has been little dedicated genetic study of neurolupus. An evaluation of *TREX1*, a 3′--5′ exonuclease associated with SLE ([@B25], [@B26]), revealed a common risk haplotype in lupus patients with brain manifestations, particularly seizures ([@B27], [@B28]). While these mechanistic insights are of interest, testing of *TREX1* is unlikely to be of clinical utility ([@B27], [@B29]) given the relatively high frequency of variants in the general population ([@B30]).

Cytokines {#S2-2}
---------

There is dysregulation of multiple cytokine pathways in patients with SLE ([@B31]), and recent work has focused on the extent to which these pathways might contribute to brain damage. Approximately 80% of individuals with lupus have aberrant activation of their type I interferon pathway, identified by either a transcriptomic signature, or ultrasensitive detection of the interferon-alpha proteins ([@B32], [@B33]). Detailed longitudinal studies have shown that activation of this pathway influences lupus disease phenotype ([@B33]).

The ability of type I interferon proteins to cause brain damage and affect mood is well documented in clinical trials of recombinant type I interferon proteins ([@B34]--[@B36]). Activation of the type I interferon response in the post-mortem brains of lupus patients has been shown ([@B37]), and multiple cell types within the brain, including endothelial cells, microglia, and neurons, respond to type I interferon activation.

Many other cytokines are dysregulated in SLE, with potential neurotoxic effects. For example, IL-6 has been associated with cognitive dysfunction in these patients and causes brain disease in brain-targeted overexpression experiments ([@B38], [@B39]). Type II interferons, interleukins (IL-2, IL-12, IL-18, IL-23), and TNF cytokine families are all dysregulated in lupus and their roles in brain disease are being evaluated ([@B40]).

Inflammatory Cells {#S2-3}
------------------

Although B cells and T cells undoubtedly play an important role in the pathogenesis of SLE, neuropathological analyses in individuals with lupus show little in the way of immune cell infiltration within the brain ([@B41]). This contrasts with other neuroinflammatory diseases such as multiple sclerosis (MS) where abundant B and T cells are found within inflammatory brain lesions ([@B42]). There has been an increasing focus on how brain-resident immune cells, such as microglia, might mediate brain disease. Recent elegant studies have shown that microglia are sensitive to elevated circulating cytokines such as type I interferon, and the resulting activation can lead to activation of a number of effector pathways within these cells, including the ability to engulf and "prune" synaptic connections ([@B37], [@B43]). These studies show how dysregulated cytokines can cause structural brain damage by manipulating the normal physiological processes of brain-resident immune cells.

Antibodies {#S2-4}
----------

Antibodies are a major mediator of organ damage in SLE, and antibodies directed against multiple brain antigens are frequently produced ([@B44]). The extent to which such antibodies cause neurological disease remains to be fully determined. In some cases, for example, antibodies directed against the astrocytic water channel aquaporin-4 (AQP4), there is evidence to support a causal relationship with spinal cord and optic nerve inflammation ([@B21], [@B45]). Antibodies against neuronal cell surface proteins such as the NMDA-receptor (NMDA-R) have also been described in lupus, but a causal association with neurological symptomatology is less clear, despite their ability to mediate brain disease in animal models. Although anti-NMDA-R antibodies can cause a very distinct clinical phenotype of autoimmune encephalitis ([@B46]), this syndrome is rarely seen in SLE, and the degree to which lower titers of such antibodies can cause neuropsychiatric dysfunction outside this clinical picture is unclear ([@B47]). Interestingly, more classic lupus-associated antibodies directed against nucleic acids, can also cross-react with NMDA-R epitopes and cause neurological dysfunction in rodent models ([@B48]). In patients with SLE who have co-existing antiphospholipid syndrome there is a role for antiphospholipid antibodies in the mediation of thrombotic events including intracranial thromboembolism ([@B49]). Therefore, a broad spectrum of antibodies is implicated in the pathogenesis of neurolupus, though neurological expertise may be needed in their interpretation.

Pathology and Imaging {#S2-5}
---------------------

Brain biopsies are performed rarely in people with lupus. Consequently, much of our understanding of the pathological basis of neurolupus comes from post-mortem studies, which introduce a bias toward severe disease. The first dedicated studies identified prominent cerebral small vessel disease as a major neuropathological feature in most cases ([@B50]). Importantly, this is not a small vessel vasculitis, but rather a noninflammatory microangiopathy associated with microinfarction ([@B50]). Pathological changes of small blood vessels include necrosis of the vessel wall, endothelial cell proliferation, and hypertrophy ([@B41], [@B50], [@B51]). Subsequent studies have confirmed these findings ([@B52], [@B53]). Paired pathology-imaging studies show that these cerebral small vessel lesions seen on brain pathology correspond to "white matter hyperintensities" identifiable on MRI of the brain ([@B54]). These MRI abnormalities are seen in the majority of people with lupus, even with mild neurological symptomatology (Figure [3](#F3){ref-type="fig"}A) ([@B18]). Sophisticated MRI imaging techniques such as diffusion imaging and quantitative tractography can map the brain's white matter tracts and have identified evidence of microstructural damage in SLE (Figure [3](#F3){ref-type="fig"}C), although robust association between such changes and neurological dysfunction remains unclear ([@B38]).

![Magnetic resonance imaging (MRI) imaging in lupus brain disease. **(A,B)** Fluid-attenuated inversion recovery MRI scan of a representative individual with lupus, showing accelerated cerebral small vessel disease, highlighted red arrows. **(C,D)** Advanced MRI techniques such as diffusion tensor imaging and tractography can allow identification of individual white matter tracts and parameters such as mean diffusivity can identify microstructural disease. Tractography images of lupus patient shown, each line represents individual white matter tract. Credit: Mark Bastin, Joanna Wardlaw, and Stewart Wiseman.](fimmu-09-01146-g003){#F3}

Clinical Approach in Neurolupus {#S3}
===============================

The European League against Rheumatism recommendations for management of neurolupus emphasizes the importance of careful evaluation of new neurological events in individuals with SLE ([@B55]). It is important to remember that neurological symptoms may not be caused by lupus, and may simply represent highly prevalent neurological disease such as migraine or tension headache. Furthermore neurological symptoms may be caused directly or indirectly by drug therapies ([@B14], [@B56]). As such investigation of these symptoms should involve a detailed history, careful examination and further investigation where indicated, including MRI scan, cerebrospinal fluid analysis, and neurophysiology ([@B56]). Multidisciplinary discussion with a neurologist with an interest in neuroinflammatory disease and SLE can help.

Recognized Clinical Syndromes {#S3-1}
-----------------------------

The recognized clinical neurological syndromes associated with lupus are based loosely on the framework of the ACR criteria.

### Stroke {#S3-1-1}

The earliest descriptions of lupus brain disease emphasized a prominent role for neurovascular disease ([@B4]). Subsequent studies have shown that stroke occurs more frequently in people with SLE than in the general population, with ischemic stroke developing in up to 20% of lupus patients ([@B57]--[@B61]). This observation of an increased stroke risk has been confirmed in large prospective registry based studies ([@B59]) and meta-analyses ([@B61]). Recognized risk factors, such as hypertension, smoking, and hypercholesterolemia may play an important role in this increased risk ([@B60]), but do not fully account for the excess of cases, implicating an additional inflammatory etiology ([@B62]). As such, addressing the modifiable stroke risk factors of smoking, diet, and blood pressure, is an important priority for lupus patients. Patients with lupus who present with stroke should be carefully evaluated for the antiphospholipid syndrome, given that this may direct a different strategy based on anti-coagulation rather than anti-platelet therapies. Intracranial vasculitis causing stroke---either ischemic or subarachnoid hemorrhage---is rare in SLE, but can sometimes occur and may be identified by abnormal angiographic appearances or biopsy ([@B63]--[@B65]), highlighting the heterogeneity of underlying mechanisms which drive neurovascular disease in lupus.

### Small Vessel Disease (SVD) {#S3-1-2}

Cerebral SVD is a disorder of the brain's perforating arterioles with typical MRI brain imaging features which include white matter hyperintensities (WMH, Figure [3](#F3){ref-type="fig"}A). Such appearances can occasionally cause diagnostic confusion with MS, although improved imaging should aid the distinction. Accelerated cerebral SVD is a major cause of dementia in the general population, although the neurological significance of these findings in lupus remains to be determined ([@B18]). Quantified MRI brain studies of individuals with lupus show significantly accelerated cerebral SVD, suggesting that this is the most frequently observed radiological--pathological brain abnormality in lupus ([@B41], [@B54], [@B66]), seen even in patients with mild and inactive disease ([@B18]). It is likely that inflammatory mediators such as cytokines play a direct role ([@B67]), though the precise factors---and whether they might be more accurately targeted---remain to be determined.

### Seizures {#S3-1-3}

Seizures can occur in approximately 5% of individuals with lupus. These are often generalized, though can also be of focal onset ([@B68], [@B69]). It remains unclear as to whether such events represent a form of autoimmune epilepsy, or a lowered seizure threshold. Seizures can also occur in the context of underlying disorders, such as infection, macrophage activation syndrome (MAS) ([@B70]), or posterior reversible encephalopathy syndrome (PRES) ([@B71]), highlighting the need for appropriate investigation of seizures depending on the clinical context. There is no clear association between seizures and autoantibody formation, including the potentially epileptogenic anti-NMDA-R antibody ([@B68]). While recurrence rate of seizures appears to relatively low ([@B69]), large-scale epidemiological analyses of large databases confirm higher rates of epilepsy in people with lupus ([@B72]). Seizures should be carefully evaluated with a neurologist for underlying cause and use of anticonvulsant agents discussed in those at high risk of seizure recurrence. If anticonvulsant medication is used, particular attention may need to be paid to issues such as drug interactions and teratogenicity.

### Myelopathy {#S3-1-4}

Spinal cord disease is an uncommon but serious neurological complication in people with lupus. Over the past decade, the identification of pathogenic antibodies against glial antigens such as the AQP4 water channel has demonstrated that "lupus myelitis" can, in part, be explained by concomitant neuromyelitis optica spectrum disorder (NMOSD) ([@B73]). These autoantibodies, together with anti-myelin oligodendrocyte glycoprotein (MOG) antibodies, should be tested in spinal cord presentations, especially in the context of "longitudinally extensive transverse myelitis" where inflammation extends over at least three vertebral segments ([@B74]). The presence of AQP4 antibodies is associated with a risk of relapse and immunosuppression is typically used to prevent further events. The B-cell depleting monoclonal antibody rituximab is increasingly used as a first- or second-line agent ([@B21], [@B74], [@B75]). Antibodies against AQP4 can be generated in people with lupus without an opticospinal inflammatory event. These antibodies can be associated with other neurological syndromes such as intractable hiccups and vomiting due to lesions in the *area postrema*, highlighting the broadening spectrum of AQP4-associated neurological disease, both with and without lupus ([@B45], [@B76]). Spinal cord disease in SLE is heterogeneous and short transverse myelitis and ischemic transverse myelitis can also occur ([@B22], [@B77]). Our increased understanding of the pathogenesis of spinal cord disease in lupus highlights that a myelopathic presentation can be caused by multiple different etiologies ([@B77]), with diverse treatment options ([@B23]), requiring careful evaluation (Figure [2](#F2){ref-type="fig"}C).

### Meningitis {#S3-1-5}

Meningitis, as described in the ACR case definitions, specifically refers to an autoimmune aseptic meningitis. This can occur in lupus patients in isolation, but can also accompany other events such transverse myelitis ([@B78]). It is rare. Given that many individuals with lupus are immunosuppressed, a critical differential diagnosis is one of infectious meningitis caused by typical or opportunistic pathogens. A broad spectrum of pathogens including *Cryptococcus neoformans* and *Listeria monocytogenes* can cause meningitis in lupus patients and microbiological advice should be sought ([@B78]). The clinical presentation of opportunistic organisms may vary, for example, fungal meningitis or listeriosis may present with raised intracranial pressure and cranial neuropathies rather than meningism and fever ([@B78]). Aseptic meningitis has also been described as a consequence of drugs used to treat lupus, including NSAIDs ([@B79]).

### Movement Disorders {#S3-1-6}

Chorea, a hyperkinetic movement disorder, has been reported in lupus patients ([@B80]), although reversible forms of parkinsonism, a hypokinetic movement disorder, has also been described, particularly in young-onset disease ([@B81], [@B82]). Myoclonus has also been described ([@B83]). The etiology of these movement disorders is poorly understood and neuroimaging studies do not usually identify evidence of a localizing lesion ([@B84]). Both ischemic and antibody-mediated causes have been postulated, though not convincingly demonstrated.

### Demyelinating Syndrome {#S3-1-7}

An association between lupus and MS-like brain changes have been suggested, and sometimes termed "lupoid sclerosis" ([@B85]). However, many such studies pre-date high quality MRI brain imaging which has greatly facilitated accurate diagnosis of MS. Much of this confusion stems from the superficial similarities between the presence of small white matter lesions on the MRI brain scans of patients with both MS and lupus. Advances in our understanding of the pathogenesis of MS in the past decades highlight that these lesions are distinct from those observed in lupus ([@B86]). Lesions in MS can usually be distinguished from those of lupus with MRI brain imaging. For example, lesions in lupus rarely enhance and correlate at a pathological level with small vessel injury ([@B54]), rather than the lymphocytic infiltration and demyelination seen in MS lesions ([@B42], [@B86]). Active MS lesions often display incomplete ring enhancement, and typically occur in a more periventricular distribution. True co-existence of lupus and MS is uncommon ([@B19], [@B87]), and there is no convincing evidence that lupus can cause an MS-like syndrome ([@B87]). In patients with both lupus and convincing clinical and paraclinical evidence of MS ([@B88]), a more plausible explanation is that, as is sometimes seen autoimmunity, the two diseases co-exist in a single individual ([@B89]). This presents a specific management challenge of identifying immunotherapies that might offer efficacy against both diseases.

### Headache {#S3-1-8}

Headache is a highly prevalent disorder in people with SLE ([@B90]), but there is no convincing evidence that this incidence is higher than that seen in the general population ([@B91]). Thus the entity of "lupus headache" is controversial ([@B92]). Headache in individuals with lupus should be approached in the same way as in the general population, noting the broader differential diagnosis of any new acute headache to include a higher risk of infectious and neurovascular etiologies ([@B64]).

### Psychiatric Disease {#S3-1-9}

The term "lupus psychosis" has been used to describe single or repeated episodes of thought disorders such as hallucinations and delusions occurring in people with SLE ([@B93], [@B94]). Like many neuropsychiatric symptoms, the biology of psychosis remains poorly understood, although the possibility of an autoimmune contribution is the subject of intense current research interest ([@B47], [@B95]). Individuals with lupus are exposed to a number of biological substances which can cause psychosis, in particular corticosteroids and circulating antibodies directed against the NMDA-R ([@B47]). An association has also been identified between psychosis in lupus and anti-ribosomal-P antibodies ([@B96]), which can react against neuronal cell surface antigens ([@B97]). However, while antibodies directed against dsDNA, NMDA-R, and ribosomal-P may exhibit some neurotoxic effects in adoptive transfer experiments, their role in mediating psychiatric symptomatology and other brain symptoms in humans is not clear ([@B98]). A proportion of psychotic events in lupus are temporally related to corticosteroid use, although such observations are likely to be confounded by increases in systemic disease activity which might precede increased steroid dose ([@B99]--[@B101]). Differentiation of steroid-induced psychosis from lupus-associated psychosis is particularly challenging ([@B100]).

Depression and anxiety are common in the general population and observed more frequently in chronic disease states. It is, therefore, not surprising that about 15% of patients diagnosed with lupus develop mood disorders and 5% an anxiety disorder ([@B12], [@B102]). However, the use of both interviews and validated scales to quantify affective disorders suggest that the prevalence of mood and anxiety disorders may be significantly higher, around 20--40% ([@B103]--[@B106]). It has been established in clinical trials of therapeutic cytokines that inflammatory factors, such as type I interferon proteins, can induce depressive illness in humans ([@B36], [@B107]). Therefore, the degree to which lupus-related inflammatory factors contribute to the high burden of psychiatric disorders in this condition remains unresolved.

### Cognitive Dysfunction {#S3-1-10}

Longitudinal cognitive assessment in people with SLE show that cognition can vary over time ([@B108], [@B109]), though true dementia is not common ([@B110]). There is no clear association with lupus activity ([@B111]). Screening tools are of use to identify cognitive dysfunction in the clinic and should prompt more detailed neuropsychological testing if abnormal ([@B112]). However, cognitive changes can be transient and their substrate poorly defined. While some correlation with MRI abnormalities has been identified, this is not a robust association ([@B113]). Associations with elevated cytokines such as IL-6 have also been identified, but again a causal relationship is unclear ([@B38]). Evaluation of cognitive symptoms in people with lupus requires careful clinical evaluation, paying attention to additional factors such as depression and medication which can contribute to cognitive dysfunction. Neither corticosteroids ([@B114]) nor NMDA-R antagonists ([@B115]) have been shown to improve cognitive functioning in SLE, though cognitive rehabilitation approaches have shown some promise ([@B116]).

### Rare Entities {#S3-1-11}

Posterior reversible encephalopathy syndrome is a clinical--radiological syndrome of headache, seizures, and encephalopathy associated with white matter changes which occur mainly toward the posterior regions of the brain ([@B117]). Despite its name, the neurological damage caused by PRES is not necessarily reversible and can occur throughout the brain. A number of cases of PRES in people with SLE have been reported ([@B71]), but this syndrome can be confounded by associations with immunosuppressive medications and uncontrolled hypertension, and, therefore, the precise etiological factors are not fully understood ([@B71]). PRES-like appearances on neuroimaging can be mimicked by venous sinus thrombosis, which is an important differential diagnosis.

Another rare manifestation of lupus is the macrophage activation syndrome which can occur with prominent neurological involvement including seizures and encephalopathy ([@B70]). This is an important differential diagnosis of the acutely unwell lupus patient with multisystem involvement and requires prompt identification and treatment.

### Inflammatory Neuromuscular Disease {#S3-1-12}

Neuromuscular disease is an important cause of morbidity in SLE. The ACR neurolupus case definitions consider cranial nerve, peripheral nerve, and neuromuscular junction disease together, stopping at the motor end-plate and excluding muscle disease, which is classified separately. Muscle disease is, therefore, not reviewed in depth here, although it should be noted that a spectrum of inflammatory muscle disease can occur in about 10% of patients with SLE, including myositis and vasculitis, sometimes requiring biopsy confirmation ([@B118]--[@B120]).

### Peripheral Neuropathy {#S3-1-13}

Peripheral neuropathy can occur in approximately 8% of patients with lupus, presenting mainly as a symmetrical polyneuropathy ([@B121], [@B122]). Mononeuritis multiplex can also occur occasionally in lupus and is associated with small vessel vasculitic change on nerve biopsy, often developing during periods of high lupus activity ([@B123], [@B124]). Prospective studies, based on electrophysiological studies rather than symptoms, suggest that the commonest electrophysiological pattern is that of a sensorimotor axonal neuropathy ([@B122]). Among lupus-associated neuropathies, the identification of demyelinating inflammatory neuropathies is of particular importance, given the demonstrated response of such neuropathies to intravenous immunoglobulin ([@B125]). Identification of inflammatory demyelination on nerve conduction studies should provoke examination of the CSF and a search for paraproteinemic comorbidities ([@B126]). Very rarely, Guillain--Barré Syndrome---an acute inflammatory neuropathy---has been observed ([@B127]) as has myasthenia gravis.

### Cranial Neuropathy {#S3-1-14}

Optic neuropathies, manifesting as either optic neuritis or ischemic optic neuropathy, have been observed in SLE ([@B128]--[@B132]). Given the association of NMOSD with lupus, evaluation of anti-AQP4/MOG antibodies is important and may potentially guide treatment ([@B74], [@B133]). Cranial neuropathies affecting all cranial nerves have been reported in lupus ([@B134]--[@B137]), either as single events or as a cranial mononeuritis multiplex ([@B137], [@B138]).

### Functional Disorders {#S3-1-15}

Functional symptoms are real but are not caused by underlying neurological disease. Functional neurological disorder is a common cause of neurological symptoms, in both general medicine and neurology clinics, and can, therefore, frequently co-exist with inflammatory diseases such as lupus ([@B139]). Incorrectly attributing functional symptoms to an inflammatory cause can lead to an inappropriate escalation in immunotherapy or unnecessary investigation. A specialist neurological opinion can help to identify positive findings of functional neurological disease. The incidence of functional symptomatology in lupus and other inflammatory diseases is unknown and merits further study ([@B139]).

Treatment of Neurolupus {#S3-2}
-----------------------

While efforts have been made to guide best practice in the diagnosis and management of neurolupus, there is only a weak evidence base on which to develop such recommendations ([@B55]). There have been a handful of clinical studies for the treatment of lupus-associated neurological disease, none which provide high quality evidence. A small randomized trial of cyclophosphamide suggested potential benefit, but interpretation of these data are limited by small sample size and methodological issues ([@B140], [@B141]). There have also been observational studies of azathioprine ([@B142]) and rituximab ([@B143]), but the high degree of variability of clinical symptomatology and a lack of standardized neurological outcome measures makes these results difficult to interpret. Furthermore, meaningful metrics of neurological disease are rarely captured in large lupus clinical trials, and patients with neurological disease are often excluded from such studies ([@B144]).

Future Directions {#S4}
=================

Systemic lupus erythematosus is a strong candidate for a "personalized immunotherapy" approach, since individual patients may have different molecular pathways driving their disease. Longitudinal studies of lupus patients, together with their peripheral transcriptomic responses, support this approach to developing targeted therapies. These analyses show that targetable pathways---or combinations of pathways---can drive different aspects of lupus ([@B33]). For example, activation of the type I interferon response is an important determinant of organ-specific disease and is implicated in aspects of brain disease. Similarly, B-cell pathways play an important role in neurological syndromes caused by pathogenic autoantibodies. Thus, with the advent of more accurate biomarkers to identify aberrant immunological pathways, heterogeneous populations could be divided into those who are predicted to respond to targeted therapies, acting as a basis for rational trial design (Figure [4](#F4){ref-type="fig"}) ([@B32], [@B37], [@B145]). If this approach is to provide a logical framework for developing therapies, then we need to incorporate such a molecular understanding into clinical classification.

![A stratified medicine approach for neurolupus. Brain disease in lupus is clinically heterogeneous (left), but may be driven by certain molecular pathways (e.g., type I interferon pathway, pathogenic autoantibodies), allowing stratification of populations. Improvements in biomarkers will allow identification of aberrant pathways in patients, such that they can be directed to clinical trials targeted at the specific pathway. Central to the success of such a strategy is the development of brain biomarkers (e.g., magnetic resonance imaging scans, markers of brain damage) to supplement clinical assessment.](fimmu-09-01146-g004){#F4}

At present, the classification system for neurological disease in lupus is largely based on neurological syndromes and does not incorporate a pathophysiological understanding of the disease (Figure [2](#F2){ref-type="fig"}). The need to move from a syndromic toward a mechanistic classification is perhaps best exemplified by spinal cord disease in lupus (Figure [2](#F2){ref-type="fig"}C). The 1999 ACR case definitions refer to a broad syndrome of "lupus myelopathy." However, as we describe above, our understanding of the pathogenesis of spinal cord disease in lupus has advanced, together with the discovery of strong biomarkers and improved imaging. It is clear that "lupus myelopathy" can be caused by at least three different pathophysiological processes. These include antibodies against AQP4, antibody-independent inflammation, and spinal vascular disease. It is likely that each of these different mechanisms may require a different therapeutic approach. Furthermore, some syndromes, such as "lupus headache," may not exist at all. As such the classification system used in neurolupus requires substantial revision, reflecting the transition to a molecular understanding of disease.

A critical step in the future success of neurolupus clinical trials will be improving the quantification of neurological outcomes. There is a particular need to develop validated imaging and laboratory biomarkers of neurological disease in lupus which can supplement complex clinical assessment. MRI brain scans are invariably abnormal in lupus, and change over time. As such, imaging biomarkers may play a role as our ability to quantify macrostructural and microstructural damage (Figure [3](#F3){ref-type="fig"}). Serum and CSF biomarkers of "brain damage," such as ultrasensitive detection of neurofilament protein, have been developed as a surrogate marker for clinical trials in neuroinflammatory and neurodegenerative diseases ([@B146]). Thus the rapid progress in our understanding of both pathophysiology and biomarkers of neurolupus is providing a much-needed roadmap to advance the field.

Summary {#S5}
=======

Neurological disease is an area of major unmet need for people with lupus, providing a complex conceptual and practical challenge. An improved molecular understanding of how lupus can damage the brain and nervous system is providing opportunities to pursue stratified medicine approaches. Advancing the field will require our tools for classifying and measuring neurological disease in lupus to be reevaluated.
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